Monitor for any data readouts or trial enrollment updates from the upcoming conferences. The Phase 3 initiation timeline remains unchanged — no catalyst from this filing alone.
Price Chart
Executive Summary
OKYO Pharma announced its participation and presentation at upcoming ophthalmic conferences (Eyecelerator, American Academy of Optometry, American Academy of Ophthalmology) in September-October 2026. The company reiterated its plan to initiate a global Phase 3 pivotal trial for urcosimod in neuropathic corneal pain (NCP) in the second half of 2026. This is a routine corporate update with no new clinical data or financial results.
Key Facts
- OKYO will present at Eyecelerator on October 8, 2026 in New Orleans.
- CEO Robert J. Dempsey will present 'Addressing Unmet Needs in Corneal and Anterior Segment Diseases'.
- Leadership team will attend American Academy of Optometry (Sept 30-Oct 1) and American Academy of Ophthalmology (Oct 9-12).
- Company plans to initiate a global Phase 3 pivotal trial for urcosimod in NCP in the second half of 2026, enrolling ~111 patients.
- No new clinical data, financial results, or material agreements were disclosed.
Financial Impact
No financial figures disclosed.
Risk Factors
- Clinical-stage biotech with no approved products or revenue.
- Phase 3 trial execution and enrollment risks.
- Reliance on future financing for continued operations.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-044760 |
| Exhibit: ex99-1.htm | 0001493152-26-044760 |
| Document: 0001493152-26-044760-index-headers.html | 0001493152-26-044760 |
| Document: 0001493152-26-044760-index.html | 0001493152-26-044760 |
| Document: 0001493152-26-044760.txt | 0001493152-26-044760 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 6-K | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.45 (−0.68%) |
Oct 6, 2026 21d ago | Press Release | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.45 (−0.68%) |
Sep 29, 2026 28d ago | 6-K | $1.36 $1.29 | ▼ −5.15% | ▼ −4.94% | $1.45 (+6.62%) |
Sep 8, 2026 7w ago | 6-K | $1.53 $1.45 | ▼ −5.23% | ▼ −4.76% | $1.45 (−5.23%) |
Aug 7, 2026 11w ago | Insider Cluster | $1.57 $1.52 | ▼ −3.18% | ▼ −2.87% | $1.45 (−7.64%) |
Jul 28, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▲ +1.54% | $1.45 (−11.59%) |
Jul 27, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▼ −0.24% | $1.45 (−11.59%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.45 (−2.03%) |
Jul 23, 2026 13w ago | Press Release | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.45 (−2.03%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.45 (−2.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers